福安药业子公司产品纳入国家医保药品目录

Group 1 - The core point of the article is that Fu'an Pharmaceutical (300194.SZ) announced that its subsidiary's product, Palivizumab injection, has been included in the National Medical Insurance Drug List as per the notice issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 2 - The inclusion of Palivizumab injection in the National Medical Insurance Drug List is expected to enhance the product's market accessibility and potentially increase sales [1] - This development reflects the government's ongoing efforts to expand the coverage of essential medications under the national insurance scheme [1] - The announcement may positively impact the company's financial performance and investor sentiment in the pharmaceutical sector [1]